For GLP1RA, negative influences included older age, concurrent DPP4i use (OR 0.12, 95% CI 0.08–0.16), and non‐endocrinologist prescription, whereas female sex (OR 1.35, 95% CI 1.06–1.73), dyslipidemia (OR 1.68, 95% CI 1.10–2.66), and the use of insulin (OR 3.71, 95% CI 2.83–4.85), or SU (OR 3.13, 95% CI 2.44–4.02) use were positive factors. This evidence concerns the gene INS and metabolic syndrome.